Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.76 |
| ▸ | FBP1 | P09467 | 3/20 | 0.76 |
| ▸ | GAK | O14976 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | BUB1 | O43683 | 1/20 | 0.63 |
| ▸ | KDM1A | O60341 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.63 |
| ▸ | STK17B | O94768 | 1/20 | 0.63 |
| ▸ | STK10 | O94804 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615047 | 1.00 | EGFR (0.76) | EGFRFBP1GAKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL642049 | 0.99 | EGFR (0.74) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL14862652 | 0.90 | FBP1 (0.76) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL16212531 | 0.90 | EGFR (0.78) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL15928142 | 0.87 | EGFR (0.62) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL15928192 | 0.87 | EGFR (0.62) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL667895 | 0.86 | EGFR (1.00) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL19026906 | 0.86 | FBP1 (0.65) | EGFRFBP1GAKALDH1A1MAPT | |
| SCHEMBL8088219 | 0.86 | EGFR (0.79) | EGFRFBP1GAKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507455 | 0.85 | EGFR (0.98) | EGFRFBP1GAKALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394942-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113264888-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-107556295-B | Quinazoline derivatives and process for their preparation | 正大天晴药业集团股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3050880-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-9725439-B2 | Quinazoline derivative and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-08 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| EP-3103799-A1 | QUINAZOLINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-3050880-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-07-28 | — | — | US | disclosed |
| EP-2163546-B1 | Quinazoline derivatives | PFIZER PROD INC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2163546-A1 | Quinazoline derivatives | Pfizer Products Incorporated (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | EGFR 1042/4885FBP1 3168/4885GAK 493/4885 |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEE1, WEE2, EGFR | EGFR 3/4885FBP1 1588/4885GAK 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.